The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynectics Regulatory News (SNX)

Share Price Information for Synectics (SNX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 175.00
Bid: 170.00
Ask: 180.00
Change: -7.50 (-4.11%)
Spread: 10.00 (5.882%)
Open: 182.50
High: 182.50
Low: 172.50
Prev. Close: 182.50
SNX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director’s and PDMRs' Interests in Share Schemes

2 Aug 2022 07:00

RNS Number : 5099U
Synectics PLC
02 August 2022
 

 

 

RNS

 

2 August 2022

 

 

Synectics plc

("Synectics", the "Company" or the "Group")

 

Director's and PDMRs' Interests in Share Schemes:

 

Grant of Options and amendment to performance criteria of Performance Share Plan for certain PDMRs

 

Synectics plc (AIM: SNX), a leader in the design, integration and support of advanced security and surveillance systems, announces that on 1 August 2022 (the "Date of Grant") it made an award of options ("Options") over, in aggregate, 184,000 ordinary shares of 20p each in the Company (the "Ordinary Shares") to Amanda Larnder, following her appointment as its Finance Director last month, and to certain Persons Discharging Managerial Responsibility ("PDMRs") of the Company under its existing Performance Share Plan (the "PSP"), as detailed below.

 

In addition, the Company altered the performance criteria of previous awards of Options under the PSP made to certain PDMRs, details of which are set out below.

 

Award of New Director Options

  

Name

Position

Number of Options

Amanda Larnder

Group Finance Director

124,000

 

Following this award, Mrs Larnder's total interests in Ordinary Shares comprise:

 

 

 

 

Name

 

Number of

Ordinary Shares held

Interest in Ordinary Shares in Synectics plc share schemes

 

Resultant total interest in Ordinary Shares

 

% of issued share capital

Amanda Larnder

4,326

124,000

128,326

0.72%

 

To achieve alignment with the conditions attached to similar options granted in August 2020 to Paul Webb, the Company's Chief Executive, and subsequently amended on 11 May 2022, the above one-off award vests over an approximately 3.6-year period, from the Date of Grant up to the announcement of the Company's audited final results for the financial year ending 30 November 2025. The Options are divided into two equal tranches, with vesting dependent, inter alia, on the achievement of performance criteria for each of the Company's financial years ending 30 November 2024 and 2025. The Options are exercisable at nil cost and must be exercised within ten years of the Date of Grant.

 

The performance criteria will be measured according to the average of the Compound Annual Growth Rate ("CAGR") of the Total Shareholder Return ("TSR") and the CAGR of Adjusted Underlying Diluted Earnings Per Share ("EPS") for each of the two relevant performance periods of approximately three and four years respectively. If this average is 20% or more, 100% of that tranche of Options will vest. If this average is above 10% and below 20%, between 0% and 100% of the Options will vest (on a straight-line basis). 75% of any Options not vesting at the three-year vesting point may be carried forward to the following year. Any Options not vesting at the four-year point will lapse. The baseline for calculating the CAGR of TSR is £1.35 per share, and the baseline for calculating the CAGR of EPS is 11.87 pence per share (being the equivalent of the Company's EPS in the financial year ended 30 November 2019).

 

Award of New PDMR Options

 

Name

Position

Number of Options

Greg Alcorn

Director of Sales, Synectic Systems

20,000

David Gavin

Director of Operations, Synectic Systems

20,000

Iain Stringer

Managing Director, Synectics Security

20,000

 

Following these awards, the total interests of these PDMRs in Ordinary Shares comprise:

 

 

 

 

Name

 

Number of

Ordinary Shares held

Interest in Ordinary Shares in Synectics plc share schemes

 

Resultant total interest in Ordinary Shares

 

% of issued share capital

Greg Alcorn

-

46,609

46,609

0.26%

David Gavin

-

40,000

40,000

0.22%

Iain Stringer

12,210

40,000

52,210

0.29%

 

Under the PSP, selected employees are entitled to exercise an option to receive a certain number of Ordinary Shares at any time after a three-year vesting period, exercisable at nil cost. The number of Ordinary Shares that are awarded at the end of the three-year period is dependent on the achievement of certain performance criteria and must be exercised within ten years of the Date of Grant.

 

As above, vesting of the PSP award is measured according to the average of the CAGR of the TSR and the CAGR of EPS. If this average is 20% or more, 100% of the award will vest. If this average is above 10% and below 20%, between 0% and 100% of the award will vest (on a straight-line basis). The same baselines apply as for the new Director Options set out above.

 

 

Amendment to performance criteria of PSP for certain existing PDMRs

 

In addition to the above new awards of Options, the Company announces that on 1 August 2022, it altered the performance criteria of the PSP relating to previous awards of options made by the Company to certain PDMRs in August 2020 and March 2021 ("Existing PDMR Options") over, in aggregate, 60,000 Ordinary Shares, details of which are set out below (the "Revised Performance Criteria").

 

The variation of the performance criteria is intended to align the performance criteria for the Existing PDMR Options with the amendment to the awards for the then executive Directors of the Company as announced on 11 May 2022 and, therefore, restore the function of the Existing PDMR Options both in aiding retention of, and incentivising, the Company's PDMRs to achieve stretching financial targets in the interests of all Synectics' shareholders.

 

The following awards were made by the Company to certain PDMRs under the PSP on 7 August 2020 and 3 March 2021:

 

Name

Number of Options

Date of Grant

Greg Alcorn

20,000

7 August 2020

Iain Stringer

20,000

7 August 2020

David Gavin

20,000

3 March 2021

 

The vesting periods of the Existing PDMR Options remain the same, being from the Date of Grant up to the announcement of the Company's audited final results for the financial year ending 30 November 2023, depending on the achievement of the Revised Performance Criteria, as set out below, at the measurement date. The Existing PDMR Options remain exercisable at nil cost and must be exercised within ten years of the Date of Grant.

 

Revised Performance Criteria

 

The revised performance criteria will continue to be measured according to the average of the CAGR of the TSR and the CAGR of EPS achieved following the announcement of the Company's audited final results for the financial year ending 30 November 2023.

 

If this average is 20% (previously 25%) or more, 100% of the Existing PDMR Options will vest. If this average is above 10% (previously 15%) and below 20% (previously 25%), between 0% and 100% of the Existing PDMR Options will vest (on a straight-line basis). The same baselines apply as for the new Director Options and the new PDMR Options set out above.

Any entitlement under the PSP will lapse on cessation of employment prior to the end of the vesting periods, unless cessation of employment is by reason of redundancy, ill health or death.

 

All PSP awards previously made to David Bedford, the Company's former Group Finance Director, have now lapsed.

 

Should the performance criteria be met in full or in part for both the new Director Options and the new PDMR Options, and should the Revised Performance Criteria be met in full or in part for the Existing PDMR options, it is intended that the appropriate number of Options to be exercised will be satisfied from any unallocated Ordinary Shares already held by the Company's employee benefit trust with any balance to be satisfied from a new issue of Ordinary Shares.

 

Full details of the PSP are set out in the Company's most recent Annual Report for the year ended 30 November 2021, copies of which are available on the Company's website, www.synecticsplc.com.

 

For further information, please contact:

 

Synectics plc

David Coghlan, Chairman

Claire Stewart, Company Secretary

Tel: +44 (0) 114 280 2828

www.synecticsplc.com info@synecticsplc.com

 

Shore Capital Tom Griffiths / David Coaten

Tel: +44 (0) 207 408 4050

 

About Synectics plc

 

Synectics (AIM: SNX) is a leader in the design, integration and support of advanced security and surveillance systems that enable clients around the world to protect their people, communities, and assets.

 

Founded over 30 years ago, Synectics has deep industry experience across gaming, energy, urban transport, public space and critical infrastructure projects. The group's expert engineering teams work in partnership with customers to create integrated product and technology platforms, proven in the most complex and demanding operating environments.

 

Find out more at www.synecticsplc.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCUAOVRUSUWRAR
Date   Source Headline
27th Nov 201811:29 amRNSDirector/PDMR Shareholding
29th Oct 201810:04 amRNSDirector/PDMR Shareholding
5th Oct 20187:00 amRNSDirector/PDMR Shareholding
25th Sep 20187:00 amRNSDirectorate Change
28th Aug 20187:00 amRNSSynectics secures UK custodial sites
14th Aug 20184:00 pmRNSDirector/PDMR Shareholding
17th Jul 20187:00 amRNSInterim Results
27th Jun 20187:00 amRNSNotification of Interim Results
1st Jun 20187:00 amRNSDirectorate Change
30th May 20183:23 pmRNSHolding(s) in Company
23rd May 20187:00 amRNSContract Win
11th May 20183:38 pmRNSDirector/PDMR Shareholding
27th Apr 201811:42 amRNSDirector/PDMR Shareholding
26th Apr 20181:12 pmRNSResult of AGM
26th Apr 20187:00 amRNSAGM Statement
29th Mar 20182:09 pmRNSDirector/PDMR Shareholding
27th Mar 20184:52 pmRNSHolding(s) in Company
26th Mar 20187:00 amRNSContract Win
21st Mar 20187:01 amRNSAnnual Report and Notice of AGM
21st Mar 20187:00 amRNSDirectorate Change
20th Feb 20187:00 amRNSFinal Results
23rd Jan 20187:00 amRNSNotification of Final Results
8th Jan 20183:19 pmRNSElectronic Communication with Shareholders
4th Jan 20181:15 pmRNSHolding(s) in Company
13th Dec 20171:43 pmRNSHolding(s) in Company
12th Dec 20177:00 amRNSTrading Update
1st Dec 20175:35 pmRNSAIM Disclosure Update
30th Oct 20174:40 pmRNSDirector/PDMR Shareholding
16th Oct 20173:23 pmRNSDirector/PDMR Shareholding
22nd Sep 20173:02 pmRNSDirector/PDMR Shareholding
21st Sep 20173:58 pmRNSHolding(s) in Company
6th Sep 201710:01 amRNSDirector/PDMR Shareholding
29th Aug 20175:11 pmRNSHolding(s) in Company
18th Jul 20177:00 amRNSInterim Results
6th Jul 20177:00 amRNSNotification of Interim Results
6th Jun 20175:54 pmRNSRe-appointment of Auditor
26th May 201710:04 amRNSDirector/PDMR Shareholding
28th Apr 20174:01 pmRNSDirector/PDMR Shareholding
27th Apr 20171:08 pmRNSResult of AGM
27th Apr 20177:00 amRNSAGM Statement
11th Apr 20177:00 amRNSContract Wins
24th Mar 20172:43 pmRNSPosting of Annual Report and AGM Notice
7th Mar 20179:55 amRNSDirector/PDMR Shareholding
2nd Mar 201711:32 amRNSDirector/PDMR Shareholding
21st Feb 20177:00 amRNSFinal Results
30th Jan 20177:00 amRNSNotification of Final Results
10th Jan 20177:00 amRNSAdoption of Financial Reporting Standard 101
8th Dec 20167:00 amRNSYear End Trading Update
21st Oct 20162:20 pmRNSDirector/PDMR Shareholding
19th Jul 20167:01 amRNSContract Wins

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.